About Glycostem Therapeutics

Glycostem Therapeutics is a Netherlands based lifescience company advancing the science of cellular immunotherapy by creating breakthroughs in the expansion and differentiation of hematopoietic stem cells.

Glycostem Therapeutics has developed a new and innovative cell culture system for the ex-vivo generation of clinically relevant amounts of NK-cells.   

Glycostem Therapeutics pursues an open project collaboration policy towards joint development of cellular immunotherapeutics for treatment of leukemia, lymphomas and other forms of cancer.   

ProGraft Study for Improving UCB transplantations

As per January 1st, 2011 Glycostem Therapeutics joined the Dutch ProGraft Study, together with Erasmus Medical Centre Rotterdam, Utrecht University and GE Healthcare.

The objective of the ProGraft study is to improve cord blood stem cell homing and engraftment.

Glycostem Therapeutics’ proprietary GBGM® expansion / differentiation technology for Hematopoietic Stem Cells (“HSC”) plays a central role in the ProGraft Study together with technology for down-regulating HSC differentiation.
 
A group of 15 patients will receive a transplant with HSC’s generated via this new method.
 
A second part of the study focuses on the visualization of the efficacy of the treatment. HSC’s will be labeled with metal spheres, so that they can be seen on an MRI scan.

Although the technique already exists, it will be applied in this manner for the first time during the ProGraft study.
 
For details of the ProGraft study, see http://www.tipharma.com/projects/drug-formulation-delivery-and-targeting...